RecruitingNCT04299022

Safety, Efficacy, & Use of ViviGen Cellular Bone Matrix Allograft in Orthopaedic Fracture Care

Safety, Efficacy, & Use of ViviGen Cellular Bone Matrix Allograft in Orthopaedic Fracture Care: A Multi-Center Prospective Registry and Retrospective Data Collection Study

Sponsor

LifeNet Health

Enrollment

250 participants

Start Date

Jun 1, 2021

Study Type

OBSERVATIONAL

Conditions

Fractures, Bone Fractures, Open Nonunion of Fracture Fractures, Ununited Fracture, Tibial Fracture of Femur Fracture Arm

Summary

Prospective registry and retrospective data collection study to assess the efficacy and safety of Vivigen Cellular Bone Matrix (Vivigen) in orthopaedic trauma patients who require bone grafting in the acute, delayed, non-union fracture as well as use in fusion procedure settings.

Eligibility

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Vivigen Cellular Bone Matrix for people with fracture arm, fracture of femur, and other related conditions. The study is currently recruiting participants at 4 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.